logo-loader
viewAvacta Group PLC

Avacta Plc 'making significant progress towards commercialising Affimer platform'

Capital Network analyst Riccardo Lowi discusses Avacta Group Plc (LON:AVCT) following the release of its preliminary results.

Lowi says over the last year or so, management's delivered significant progress in bringing their Affimer platform into the commercial stage, across both therapeutics and diagnostic applications.

Quick facts: Avacta Group PLC

Price: 26.5 GBX

AIM:AVCT
Market: AIM
Market Cap: £46.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

12 hours, 52 minutes ago

2 min read